American pharmaceutical company Amgen (AMGNpennslammer36500.US) rose nearly 16% at the beginning of the session to US$322.6, the largest one-day gain since 2009. In the news, Amgen's mid-term trial of a new weight-loss drug has received positive data. If the drug is approved, it will cooperate with Novo Nordisk.pennslammer36500Wegovy and Lilly's Zepbound compete.
Earlier, some media said that Amgen is trying a new weight-loss drug, whose mechanism of action is different from Novo Nordisk and Lilly products, which can prevent patients from gaining weight even if they stop taking the drug.
